Prevent concomitant use of tucatinib with CYP3A substrates, where minimal concentration improvements could result in major or daily life-threatening toxicities. If unavoidable, decrease CYP3A substrate dose according to product or service labeling.Individuals enrolled in these research experienced a analysis of OSA, SWD, or narcolepsy and were requ